Specific anti-EGFR monoclonal antibodies have already shown clinical benefits in newly diagnosed[23] and relapsed/metastatic SCCHN[24] and it is likely that novel agents that target the EGFR/Ras axis will be active in this disease. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.